Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

NCT03077412 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03077412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03077412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
April 6, 2017
Completion date
February 17, 2021
Enrollment
57 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

fistulizing crohn's disease